-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Despite the availability of antiretroviral therapy (ART), patients with advanced human immunodeficiency virus (HIV) (CD4<50) still face a high risk of tuberculosis (TB) or death
.
Recently, researchers have explored the immunological features that best predict the incidence and death of tuberculosis, and the results of the study have been published in Clin Infect Dis
immunity
The REMBER randomized clinical trial recruited 850 HIV patients (CD4 <50 cells/μL) to receive empiric tuberculosis treatment or isoniazid preventive therapy (IPT) at the beginning of ART
.
A cohort study of cases by country and treatment group was conducted (n = 257)
prevention
As a result, 52 of the 850 participants (6.
1%) developed tuberculosis; 47 (5.
5%) died (13 of whom had threatened tuberculosis)
.
The biomarkers related to tuberculosis overlap with the biomarkers related to death (IL-1β, IL-6)
In summary, in advanced HIV infections , despite the start of ART and TB preventive therapy, a simple inflammatory biomarker feature can predict those high-risk patients who are most likely to develop TB
.
This feature may be a promising stratification tool to select patients who need enhanced monitoring and benefit from new interventions
Infect
Original source:
Yukari C Manabe, et al.
A Parsimonious Host Inflammatory Biomarker Signature Predicts Incident Tuberculosis and Mortality in Advanced Human Immunodeficiency Virus in this message
